

RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

ARTICLE

BF₃·Et₂O-Mediated Intramolecular Cyclization of Unsaturated Amides: Convenient Synthesis of Dihydroquinolin-2-one-BF₂ Complexes †

Cite this: DOI: 10.1039/x0xx00000x

Received 00th xxxxxx 2014,
Accepted 00th xxxxxx 2014

DOI: 10.1039/x0xx00000x

www.rsc.org/

Xu Liu, Qian Zhang, Xiaoqing Xin, Rui Zhang, Ning Zhang,* Yongjiu Liang, and Dewen Dong*

A facile and efficient synthesis of substituted dihydropyridone-BF₂ complexes is developed *via* intramolecular cyclization of α -acyl acrylamides and α -acyl cinnamamides mediated by BF₃·Et₂O, respectively.


Introduction

Over the past decades, pyridin-2(1*H*)-ones and their analogues have attracted considerable attention of research in chemical and biological fields.^{1,2} These structural motifs can serve as efficient catalysts in a variety of proton-dependent reactions³ and valuable ligands in coordination chemistry.⁴ Furthermore, pyridin-2(1*H*)-ones are versatile intermediates in the synthesis of a wide range of *aza*-heterocycles, such as pyridines, piperidines, indolizidines, quinolines and quinolizidines.^{5,6} In particular, pyridin-2(1*H*)-one is a key unit in numerous natural products and synthetic organic compounds such as elfamycin, cerpegin and camptothecin,⁷ along with diverse bio-, physio- and pharmacological activities. To date, a variety of synthetic approaches have been well established to access pyridin-2(1*H*)-ones and their analogues, which comprise the modification of the pre-constructed heterocyclic ring by pyridinium salt chemistry⁸ and *N*-alkylation,⁹ the construction of heterocyclic skeletons from appropriately substituted open-chain precursors *via* metal-catalyzed *sp*² C-H bond amination,¹⁰ ring closing metathesis,¹¹ and Diels-Alder reaction.¹²

On the other hand, organoboron compounds have emerged as one of the most important class of organic complexes for their excellent photophysical properties and potential use in molecular sensors,¹³ biomolecular probes¹⁴ and optoelectronic devices.¹⁵ Among those reported work, β -dicarbonyl compounds are most used ligands, and the boron difluoride β -diketonates have been extensively investigated and their promising luminescence make them good candidates for optical imaging and sensing applications.^{16,17}

During the course of our studies on the synthesis of heterocycles based on β -oxo amide derivatives, we developed the synthesis of a variety of substituted pyridin-2(1*H*)-ones under Vilsmeier conditions.¹⁸ Most recently, we achieved the

synthesis of indeno[2,1-*c*]quinolin-6(7*H*)-ones from α -acyl cinnamamides mediated by PPA (Eq. 1, Scheme 1),¹⁹ divergent synthesis of quinolin-2(1*H*)-ones (Eq. 2, Scheme 1)²⁰ and pyridin-2(3*H*)-ones (Eq.3, Scheme 1) from 2-acyl penta-2,4-dienamides.²¹ Encouraged by the previous work, we are interested to examine the reaction behaviors of unsaturated amides toward BF₃·Et₂O. By this research, we developed a facile and convenient synthesis of dihydropyridone-BF₂ complexes under very mild conditions. Herein, we will report our experimental results and present a proposed mechanism involved in the cyclization reactions.


Scheme 1 Reactions of α,β -Unsaturated Amides

Results and discussion

The substrates, unsaturated amides, were prepared by Knoevenagel condensation of commercially available β -oxo amides with aryl aldehydes in the presence of piperidine and acetic acid in good yields according to reported procedures.¹⁹⁻²²

Then, we selected 2-benzylidene-3-oxo-*N*-phenylbutanamide **1a** as a model compound to investigate its reaction behavior in the presence of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (1.0 equiv.) in CH_2Cl_2 at room temperature. The reaction could proceed and furnished a product, which was characterized as 2,2-difluoro-4-methyl-5-phenyl-5,10-dihydro-2*H*-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide **2a** (in 76% yield) on the basis of its spectral and analytical data. A series of experiments revealed that the optimal results were obtained when the reaction of **1a** was performed with $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (2.0 equiv) in CH_2Cl_2 at room temperature, in which the yield of **2a** reached 88% (Table 1, entry 1).

Table 1 Synthesis of Substituted Dihydroquinolin-2-one- BF_2 Complexes **2** from α -Acyl *N*-Arylcinnamamides **1**^a



| entry | 1 | R ¹ | R ² | R ³ | R ⁴ | 2 | yield (%) ^b |
|-------|-----------|---------------------|----------------|----------------|----------------|-----------|------------------------|
| 1 | 1a | H | H | Me | H | 2a | 88 |
| 2 | 1b | 4-Me | H | Me | H | 2b | 81 |
| 3 | 1c | 2-Me | H | Me | H | 2c | 82 |
| 4 | 1d | 3-Me | H | Me | H | 2d | 79 |
| 5 | 1e | 2,4-Me ₂ | H | Me | H | 2e | 80 |
| 6 | 1f | 4-Cl | H | Me | H | 2f | 83 |
| 7 | 1g | 4-MeO | H | Me | H | 2g | 96 |
| 8 | 1h | 2-MeO | H | Me | H | 2h | 94 |
| 9 | 1i | H | H | Ph | H | 2i | 75 |
| 10 | 1j | H | 4-Me | Me | H | 2j | 87 |
| 11 | 1k | H | 2-Me | Me | H | 2k | 86 |
| 12 | 1l | H | 2-MeO | Me | H | 2l | 85 |
| 13 | 1m | H | 4-Cl | Me | H | 2m | 83 |
| 14 | 1n | H | H | Me | Et | 2n | 81 |

^a Reagents and conditions: **1** (2.0 mmol), $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (4.0 mmol), CH_2Cl_2 (5.0 mL), rt, 2.0-3.0 h. ^b Isolated yield.

Under the identical conditions as for **2a**, a range of reactions of α -acyl *N*-arylcinnamamides **1b-n** were carried out and some of the results are summarized in Table 2. All the reactions of **1b-g** bearing various electron-donating and electron-withdrawing substituents R¹ on the aryl amides proceeded smoothly to afford the corresponding dihydropyridone- BF_2 complexes **2b-g** in high yields (Table 1, entries 2–9). In the case of **1d**, 2,2-difluoro-4,8-dimethyl-5-phenyl-5,10-dihydro-2*H*-[1,3,2]dioxaborinino-[4,5-*b*]quinolin-1-ium-2-uide **2d** was exclusively obtained in 79% yield, which suggests that **1d** underwent the cyclization reaction in a regioselective manner (Table 1, entry 4). The efficiency of the cyclization proved to be suitable for **1j-m** bearing various electron-donating and electron-withdrawing substituents R² on the benzene ring affording the corresponding substituted dihydropyridone- BF_2 complexes **2j-m** in very good yields (Table 1, entries 10-13). In the same fashion, the validity of this dihydro-pyridone- BF_2 complex synthesis was further evaluated by performing **1n** bearing secondary amide, in which dihydroquinolin-2-one- BF_2 complex **2n** were obtained in high yield (Table 1, entry 14).

The structure of **2g** was further confirmed by the X-ray single crystal analysis (Figure 1). The results shown above demonstrate the efficiency and synthetic interest of the cyclization reaction of variable α -acyl *N*-aryl cinnamamides **1**.





Figure 1 ORTEP drawing of **2g**


It should be mentioned that when dihydropyridone- BF_2 complex **2h** was treated with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 1.0 equiv.) in CH_2Cl_2 at room temperature for 1.0 h, 3-acyl-6-methoxy-4-phenylquinolin-2(1*H*)-one **3h** could be obtained in 80% yield (Scheme 2). Therefore, we provided a novel and convenient synthesis of dihydropyridone- BF_2 complexes **2** and an alternative synthesis of dihydroquinolin-2-ones **3** as well.



Scheme 2. Reaction of Substituted Dihydroquinolin-2-one- BF_2 Complex **2h** with DDQ


Encouraged by the above results, we intended to explore the reaction of 2-acyl penta-2,4-dienamides under identical reaction conditions as for **2a**. However, when 2-acyl-5-phenyl-*N*-(*p*-tolyl)penta-2,4-dienamide **4a** was subjected to CH_2Cl_2 in the presence of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ at room temperature for 2.0 h, no reaction was observed. Then, the reaction of **4a** was performed in $(\text{CH}_2)_2\text{Cl}_2$ under reflux for 1.0 h and furnished a product, which was characterized as 2,2-difluoro-4-methyl-7-phenyl-8-(*p*-tolyl)-7,8-dihydro-2*H*-[1,3,2]dioxaborinino[4,5-*b*]pyridin-1-ium-2-uide **5a** (Table 2, entry 1).

Under the identical conditions as for **4a** in Table 2 entry 1, a series of reactions of 2-acyl penta-2,4-dienamides **4b-f** were carried out in the presence of $\text{BF}_3 \cdot \text{Et}_2\text{O}$, and some of the results are summarized in Table 2. All the reactions of **4b-f** bearing different aryl amide groups for R¹ and aryl groups for R² could proceed smoothly to afford the corresponding dihydropyridin-2(3*H*)-one- BF_2 complexes **5b-f** in good yields (Table 2, entries 2–7). The structure of **5d** was elucidated by NMR (¹H, ¹³C) spectra and further confirmed by means of the X-ray single crystal analysis (Figure 2).


Table 2 Synthesis of Dihydropyridin-2(3*H*)-one-BF₂ Complexes **5** from 2-Acyl Penta-2,4-Dienamides^a

| entry | 4 | R ¹ | R ² | 5 | yield (%) ^b |
|-------|-----------|----------------|----------------|-----------|------------------------|
| 1 | 4a | 4-Me | H | 5a | 70 |
| 2 | 4b | 4-MeO | H | 5b | 72 |
| 3 | 4c | 4-Cl | H | 5c | 68 |
| 4 | 4d | 2-Cl | 4-MeO | 5d | 71 |
| 5 | 4e | 2-Me | 4-MeO | 5e | 63 |
| 6 | 4f | 4-Me | 4-Me | 5f | 65 |

^a Reaction conditions: **1** (1.0 mmol), KOH (6.0 mmol), *t*-BuOH (10 mL), 80 °C, 1.0-2.0 h. ^b Isolated yields.

**Figure 2** ORTEP drawing of **5**

In contrast to the conventional acid-catalyzed Knorr quinolin-2(1*H*)-one synthesis,²³ α -acyl *N*-aryl cinnamamides **1** were found to undergo a distinct intramolecular cyclization in which the nucleophilic addition site was on the β -carbon of the α,β -unsaturated carbonyl compounds **1** instead of their α -acyl groups. On the basis of the results obtained above and the reported literatures, a plausible mechanism for the synthesis of dihydroquinolin-2-one-BF₂ complexes **2** is presented in Scheme 3. Mediated by BF₃·Et₂O, α -acyl *N*-arylcinnamamide **1** is activated by the formation of BF₂-complex intermediate **A**,^{17d,e} followed by an intramolecular Friedel-Crafts reaction to afford dihydropyridin-2(3*H*)-one-BF₂ complex **2**.²⁴ It is most possible that the BF₂-complex moiety could not provide enough activation to promote further intramolecular cyclization for **2** under the investigated conditions. As for 2-acyl penta-2,4-dienamides **4**, a BF₂-complex intermediate **B** is formed in the same way (Scheme 3). Here, it is worth noting that BF₂-complex intermediate **B** contains a 1-azatriene moiety, which under the investigated conditions may undergo a 6 π -azaelectrocyclization reaction²¹ instead of the Friedel-Crafts reaction as α -acyl *N*-aryl cinnamamide **1** did. Just like the role of hydrogen bond did in our previous work, the BF₂-complex structure provides the driving force to keep the azadiene N=C=C of **B** in a *cis* conformation that may favor the subsequent 6 π -azaelectrocyclization, and also stabilize the structure of product **5**.

**Scheme 3.** Plausible Mechanism for the Reaction of Unsaturated Amides Mediated by BF₃·Et₂O

Conclusions

In summary, a facile and convenient synthesis of substituted dihydropyridone-BF₂ complexes **3** and **5** is developed via intramolecular cyclization of unsaturated amides, α -acyl *N*-aryl cinnamamides **1** and 2-acyl penta-2,4-dienamides **4**, mediated by BF₃·Et₂O, respectively. The simple execution, readily available substrates, very mild conditions, good yields and wide range of synthetic potential of the products make this protocol much attractive. The extension of the scope of the methodology and its further applications are currently under investigation in our laboratory.

Experimental section

General

All reagents were purchased from commercial sources and used without treatment, unless otherwise indicated. The products were purified by column chromatography over silica gel. ¹H NMR and ¹³C NMR spectra were recorded at 25 °C at 300 MHz and 100 MHz, respectively, with TMS as internal standard. IR spectra (KBr) were recorded on FTIR-spectrometer in the range of 400-4000 cm⁻¹. All melting points were determined in open capillary tubes in a Thiele apparatus and are uncorrected.

Typical procedure for the synthesis of substituted unsaturated amides **1** (1a as an example).

To a 100 mL round-bottomed flask was added 3-oxo-*N*-phenylbutanamide (0.89 g, 5.0 mmol), 4-methylbenzaldehyde (0.60 g, 5.0 mmol), piperidine (0.5 mmol), acetic acid (0.5 mmol) and ethanol (30 mL). Then the mixture was stirred for 8.0 h at room

temperature. The resulting mixture was slowly poured into saturated aqueous NaCl (100 mL), and extracted with dichloromethane (3 × 30 mL). The combined organic phase was washed with water (3 × 30 mL) and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure, and the crude product was purified by flash chromatography (silica gel, petroleum ether: ethyl acetate 10:1) to give **1a** as a colorless solid (1.20 g, 86%).

Substrates **1a-k** and **1n** are known compounds (**1a** and **1j**: *J. Indian Chem. Soc.* **1981**, *58*, 168, **1c** and **1d**: *Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences*, **1949**, *228*, 576, **1b**, **1e-k** and **1n**: *Org. Lett.* **2013**, *15*, 776.)

2-(4-Methoxybenzylidene)-3-oxo-*N*-phenylbutanamide (**1l**) [E/Z=4:25]

Colorless solid: mp 91-96 °C; ¹H NMR (300 MHz, CDCl₃) (minor *E*-isomer): δ 2.45 (s, 3H), 3.86 (s, 3H), 6.94 (d, *J* = 6.0 Hz, 2H), 7.14-7.16 (m, 1H), 7.28-7.33 (m, 2H), 7.57-7.63 (m, 4H), 8.21 (s, 1H), 9.39 (s, 1H); (major *Z*-isomer): δ 2.45 (s, 3H), 3.81 (s, 3H), 6.86 (d, *J* = 6.0 Hz, 2H), 7.16 (t, *J* = 6.0 Hz, 1H), 7.35 (t, *J* = 6.0 Hz, 2H), 7.53-7.57 (m, 5H), 7.88 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 13.7, 20.5, 22.2, 26.4, 30.9, 54.8, 59.9, 114.0, 119.7, 124.0, 128.5, 131.2, 131.9, 137.3, 140.5, 145.1, 161.3, 165.8, 195.4; Anal. Calcd for C₁₈H₁₇NO₃: C, 73.20; H, 5.80; N, 4.74. Found: C, 72.81; H, 5.85; N, 4.69.

2-(4-Chlorobenzylidene)-3-oxo-*N*-phenylbutanamide (**1m**) [E/Z=2:5]

Colorless solid: mp 122-127 °C; ¹H NMR (300 MHz, CDCl₃) (minor *E*-isomer): δ 2.17 (s, 3H), 7.11-7.18 (m, 2H), 7.27-7.35 (m, 2H), 7.47-7.50 (m, 2H), 7.52 (s, 2H), 7.58 (d, *J* = 6.0 Hz, 2H), 9.28 (s, 1H); (major *Z*-isomer): δ 2.43 (s, 3H), 7.11-7.18 (m, 1H), 7.20 (d, *J* = 12.0 Hz, 1H), 7.27-7.35 (m, 4H), 7.40 (d, *J* = 9.0 Hz, 1H), 7.45 (s, 1H), 7.47-7.50 (m, 2H), 8.11 (d, *J* = 4.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 26.4, 31.1, 119.5, 119.9, 124.2, 128.6, 130.5, 135.8, 136.8, 143.1, 160.3, 165.1, 195.4, 206.3; Anal. Calcd for C₁₇H₁₄ClNO₂: C, 68.12; H, 4.71; N, 4.67. Found: C, 68.44; H, 4.75; N, 4.62.

Typical procedure for the synthesis of dihydropyridone-BF₂ complexes **2** (**2a** as an example).

To a 50 mL round bottomed flask was added **1a** (530.0 mg, 2.0 mmol), BF₃·Et₂O (5.0 mmol) and CH₂Cl₂ (10 mL). The mixture was stirred at room temperature for 1.0 h. After the substrate **1a** was consumed completely as indicated by TLC, the mixture was poured into ice water, and then extracted with dichloromethane (3 × 20 mL), the combined organic phase was washed with water (3 × 20 mL), and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure, and the crude product was purified by flash chromatography (silica gel, petroleum ether: ethyl acetate 5:1) to give **2a** as colorless solid (551.1 mg, 88%).

2,2-Difluoro-4-methyl-5-phenyl-5,10-dihydro-2*H*-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (**2a**)

Yellow solid: mp 239-240 °C; ¹H NMR (300 MHz, DMSO): δ 2.05 (s, 3H), 5.33 (s, 1H), 7.07 (d, *J* = 6.0 Hz, 1H), 7.11 (s, 1H), 7.17-

7.22 (m, 2H), 7.25 (s, 1H), 7.28 (d, *J* = 2.4 Hz, 3H), 7.32 (d, *J* = 7.5 Hz, 1H), 12.08 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 20.4, 41.5, 96.6, 117.2, 125.5, 126.4, 126.7, 126.9, 127.8, 129.0, 129.5, 132.4, 146.3, 163.8, 179.4; IR (KBr, cm⁻¹): 3352, 1624, 1610, 1593, 1526, 1493, 1333, 1119, 762, 706; Anal. Calcd for C₁₇H₁₄BF₂NO₂: C, 65.21; H, 4.51; N, 4.47. Found: C, 65.52; H, 4.48; N, 4.54.

2,2-Difluoro-4,7-dimethyl-5-phenyl-5,10-dihydro-2*H*-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (**2b**)

Yellow solid: mp 210-212 °C; ¹H NMR (300 MHz, DMSO): δ 2.03 (s, 3H), 2.17 (s, 3H), 5.26 (s, 1H), 6.98 (d, *J* = 9.9 Hz, 1H), 7.03 (d, *J* = 9.9 Hz, 2H), 7.18 (t, *J* = 6.9 Hz, 1H), 7.25 (d, *J* = 6.9 Hz, 2H), 7.30 (t, *J* = 7.5 Hz, 2H), 12.01 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 20.4, 41.7, 96.7, 117.1, 126.3, 126.8 (1), 126.8 (2), 128.4, 129.0, 129.8, 130.0, 134.9, 146.4, 163.5, 178.9; Anal. Calcd for C₁₈H₁₆BF₂NO₂: C, 66.09; H, 4.93; N, 4.28. Found: C, 65.87; H, 4.90; N, 4.22.

2,2-Difluoro-4,9-dimethyl-5-phenyl-5,10-dihydro-2*H*-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (**2c**)

Colorless solid: mp 246-247 °C; ¹H NMR (300 MHz, DMSO): 2.09 (s, 3H), 2.34 (s, 3H), 5.31 (s, 1H), 6.99 (t, *J* = 7.5 Hz, 1H), 7.06 (d, *J* = 7.5 Hz, 1H), 7.12 (d, *J* = 7.5 Hz, 1H), 7.16-7.21 (m, 1H), 7.24-7.28 (m, 3H), 7.32 (d, *J* = 7.5 Hz, 1H), 11.22 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 17.8, 20.5, 41.8, 97.0, 125.4, 126.1, 126.8, 127.0, 127.4, 128.1, 128.9, 129.2, 129.8, 130.9, 146.5, 164.6, 179.9; Anal. Calcd for C₁₈H₁₆BF₂NO₂: C, 66.09; H, 4.93; N, 4.28. Found: C, 66.35; H, 4.88; N, 4.31.

2,2-Difluoro-4,8-dimethyl-5-phenyl-5,10-dihydro-2*H*-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (**2d**)

Yellow solid: mp 261-263 °C; ¹H NMR (300 MHz, DMSO): δ 2.04 (s, 3H), 2.33 (s, 3H), 5.27 (s, 1H), 5.76 (s, 1H), 6.90 (d, *J* = 7.8 Hz, 2H), 7.13 (d, *J* = 7.8 Hz, 1H), 7.19 (d, *J* = 7.5 Hz, 1H), 7.24 (d, *J* = 7.5 Hz, 2H), 7.30 (d, *J* = 7.5 Hz, 2H), 12.02 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 20.4, 20.5, 41.2, 54.8, 96.7, 117.4, 123.5, 126.2, 126.7, 129.0, 129.3, 132.1, 137.3, 146.5, 163.8, 179.2; Anal. Calcd for C₁₈H₁₆BF₂NO₂: C, 66.09; H, 4.93; N, 4.28. Found: C, 66.42; H, 5.00; N, 4.22.

2,2-Difluoro-4,7,9-trimethyl-5-phenyl-5,10-dihydro-2*H*-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (**2e**)

Yellow solid: mp 291-293 °C; ¹H NMR (300 MHz, DMSO): δ 2.08 (s, 3H), 2.14 (s, 3H), 2.30 (s, 3H), 5.24 (s, 1H), 6.87 (s, 1H), 6.91 (s, 1H), 7.16-7.33 (m, 5H), 11.19 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 17.5, 20.2, 20.4, 41.8, 96.9, 125.8, 126.6, 126.7, 126.8, 127.6, 128.4, 129.0, 130.3, 134.4, 146.4, 164.2, 179.3; IR (KBr, cm⁻¹): 3337, 1626, 1601, 1526, 1485, 1327, 1146, 731, 706; Anal. Calcd for C₁₉H₁₈BF₂NO₂: C, 66.89; H, 5.32; N, 4.11. Found: C, 66.52; H, 5.39; N, 4.17.

7-Chloro-2,2-difluoro-4-methyl-5-phenyl-5,10-dihydro-2*H*-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (**2f**)

Yellow solid; mp 218-219 °C; ¹H NMR (300 MHz, DMSO): δ 2.05 (s, 3H), 5.37 (s, 1H), 7.11 (d, *J* = 6.0 Hz, 1H), 7.20-7.24 (m, 1H), 7.28-7.36 (m, 6H), 12.20 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 20.5, 41.3, 96.1, 119.0, 126.8, 127.1, 127.8, 128.5, 129.0, 129.2, 131.5, 145.8, 163.8, 179.9; IR (KBr, cm⁻¹): 3348, 3333, 1622, 1609, 1593, 1520, 1489, 1140, 746, 710, 696; Anal. Calcd for C₁₇H₁₃BClF₂NO₂: C, 58.75; H, 3.77; N, 4.03. Found: C, 59.10; H, 3.69; N, 4.06.

2,2-Difluoro-7-methoxy-4-methyl-5-phenyl-5,10-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (2g)

Yellow solid; mp 226-228 °C; ¹H NMR (400 MHz, DMSO): δ 2.03 (s, 3H), 3.66 (s, 3H), 5.29 (s, 1H), 6.82-6.85 (m, 2H), 7.02-7.05 (m, 1H), 7.17-7.22 (m, 1H), 7.25-7.29 (m, 3H), 7.32 (d, *J* = 7.5 Hz, 1H), 11.99 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 21.2, 43.5, 55.5, 96.1, 113.2, 115.2, 118.0, 124.8, 126.9, 127.3, 129.2, 145.2, 157.5, 163.3, 181.0; IR (KBr, cm⁻¹): 3348, 1703, 1647, 1620, 1597, 1529, 1499, 1269, 1130, 733, 698; Anal. Calcd for C₁₈H₁₆BF₂NO₃: C, 63.01; H, 4.70; N, 4.08. Found: C, 63.18; H, 4.69; N, 4.10.

Crystal data for **2g**: C₁₈H₁₆BF₂NO₃, colorless crystal, *M* = 343.13, monoclinic, *C* 2/*c*', *a* = 26.916(3) Å, *b* = 8.0515(9) Å, *c* = 17.954(2) Å, α = 90.00°, β = 123.571(2)°, γ = 90.00°, *V* = 3241.9(6) Å³, *Z* = 8, *T* = 293(2) K, *F*000 = 1512, *R* = 0.0474. CCDC deposition number: 922666. These data can be obtained free of charge *via* www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Center, 12 Union Road, Cambridge CB21EZ, UK; fax: (+44)1223-336-033; or deposit@ccdc.cam.ac.uk).

2,2-Difluoro-9-methoxy-4-methyl-5-phenyl-5,10-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (2h)

Colorless solid; mp 239-240 °C; ¹H NMR (300 MHz, DMSO): δ 2.06 (s, 3H), 3.83 (s, 3H), 5.28 (s, 1H), 6.84 (d, *J* = 8.1 Hz, 1H), 6.90 (d, *J* = 8.1 Hz, 1H), 7.04 (t, *J* = 8.1 Hz, 1H), 7.15-7.23 (m, 1H), 7.25-7.31 (m, 4H), 11.50 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 20.5, 41.5, 56.1, 96.7, 110.2, 121.0, 121.6, 125.8, 126.7, 126.9, 127.4, 129.0, 146.2, 147.8, 164.0, 179.5; IR (KBr, cm⁻¹): 3319, 1608, 1593, 1543, 1495, 1271, 1103, 750; Anal. Calcd for C₁₈H₁₆BF₂NO₃: C, 63.01; H, 4.70; N, 4.08. Found: C, 62.82; H, 4.74; N, 3.99.

2,2-Difluoro-4-methyl-5-(*p*-tolyl)-5,10-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (2i)

Yellow solid; mp 192-194 °C; ¹H NMR (300 MHz, DMSO): δ 2.04 (s, 3H), 2.22 (s, 3H), 5.27 (s, 1H), 7.05-7.11 (m, 4H), 7.15 (d, *J* = 8.1 Hz, 2H), 7.19-7.25 (m, 2H), 12.04 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 20.5, 41.2, 54.8, 96.6, 117.1, 125.4, 126.6, 127.7, 129.5 (1), 129.5 (2), 132.3, 136.0, 143.5, 163.7, 179.2; IR (KBr, cm⁻¹): 3344, 1628, 1595, 1526, 1491, 1329, 810, 762; Anal. Calcd for C₁₈H₁₆BF₂NO₂: C, 66.09; H, 4.93; N, 4.28. Found: C, 65.79; H, 5.01; N, 4.33.

2,2-Difluoro-4-methyl-5-(*o*-tolyl)-5,10-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (2j)

Yellow solid; mp 251-253 °C; ¹H NMR (300 MHz, DMSO): δ 1.92 (s, 3H), 2.34 (s, 3H), 5.52 (s, 1H), 7.03-7.08 (m, 3H), 7.12-7.18 (m, 3H), 7.20-7.26 (m, 2H), 12.08 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 19.0, 20.8, 96.5, 117.0, 125.5, 125.8, 126.6, 126.9, 127.8, 129.3, 131.4, 132.3, 134.2, 144.4, 163.6, 179.0; IR (KBr, cm⁻¹): 3354, 1622, 1591, 1521, 1493, 1047, 764; Anal. Calcd for C₁₈H₁₆BF₂NO₂: C, 66.09; H, 4.93; N, 4.28. Found: C, 66.41; H, 4.89; N, 4.32.

2,2-Difluoro-5-(4-methoxyphenyl)-4-methyl-5,10-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (2k)

Yellow solid; mp 204-206 °C; ¹H NMR (300 MHz, DMSO): δ 2.04 (s, 3H), 3.68 (s, 3H), 5.26 (s, 1H), 6.86 (d, *J* = 9.0 Hz, 2H), 7.08 (t, *J* = 9.0 Hz, 2H), 7.17 (d, *J* = 9.0 Hz, 2H), 7.21-7.25 (m, 2H), 12.03 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 20.8, 41.0, 55.4, 97.1, 114.7, 117.5, 125.8, 127.2, 128.0, 128.2, 129.9, 132.6, 139.0, 158.4, 164.1, 179.7; Anal. Calcd for C₁₈H₁₆BF₂NO₃: C, 63.01; H, 4.70; N, 4.08. Found: C, 63.39; H, 4.77; N, 4.16.

5-(4-Chlorophenyl)-2,2-difluoro-4-methyl-5,10-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (2l)

Yellow solid; mp 218-220 °C; ¹H NMR (300 MHz, DMSO): δ 2.07 (s, 3H), 5.40 (s, 1H), 7.10 (t, *J* = 7.5 Hz, 2H), 7.24 (t, *J* = 7.5 Hz, 2H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.39 (d, *J* = 8.4 Hz, 2H), 12.12 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 20.5, 40.9, 96.3, 117.3, 125.6, 125.9, 128.0, 129.0, 129.5, 131.7, 132.4, 145.2, 163.7, 179.6; IR (KBr, cm⁻¹): 3333, 1630, 1595, 1529, 1493, 1323, 1057, 760, 719; Anal. Calcd for C₁₇H₁₃BClF₂NO₂: C, 58.75; H, 3.77; N, 4.03. Found: C, 58.44; H, 3.84; N, 4.12.

2,2-Difluoro-4,5-diphenyl-5,10-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (2m)

Colorless solid; mp 282-284 °C; ¹H NMR (400 MHz, DMSO): δ 5.36 (s, 1H), 6.90 (d, *J* = 7.6 Hz, 2H), 7.09-7.19 (m, 5H), 7.26 (t, *J* = 7.6 Hz, 1H), 7.37 (d, *J* = 7.6 Hz, 1H), 7.45-7.50 (m, 4H), 7.56 (t, *J* = 6.8 Hz, 1H), 12.41 (s, 1H); ¹³C NMR (100 MHz, DMSO): δ 41.4, 97.2, 117.1, 125.7, 126.1, 126.3, 126.7, 127.8, 127.9, 128.6, 128.7, 129.4, 131.2, 132.4, 133.6, 145.6, 165.1, 174.8; IR (KBr, cm⁻¹): 3312, 1628, 1589, 1580, 1522, 1489, 1132, 762, 702; Anal. Calcd for C₂₂H₁₆BF₂NO₂: C, 70.43; H, 4.30; N, 3.73. Found: C, 70.01; H, 4.19; N, 3.81.

10-Ethyl-2,2-difluoro-4-methyl-5-phenyl-5,10-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]quinolin-1-ium-2-uide (2b)

Colorless solid; mp 189-191 °C; ¹H NMR (400 MHz, DMSO): δ 1.31 (t, *J* = 6.9 Hz, 3H), 2.12 (s, 1H), 4.14-4.24 (m, 2H), 5.34 (s, 1H), 7.16-7.23 (m, 3H), 7.25-7.32 (m, 4H), 7.36 (d, *J* = 7.8 Hz, 1H), 7.39 (t, *J* = 7.8 Hz, 1H), 7.45 (d, *J* = 7.8 Hz, 1H); ¹³C NMR (100 MHz, DMSO): δ 13.0, 20.8, 39.1, 41.4, 97.5, 116.9, 126.3, 127.0, 127.4, 128.5, 129.5, 130.4, 133.8, 146.2, 163.6, 179.3; IR (KBr, cm⁻¹): 1603, 1580, 1518, 1487, 1337, 1138, 756, 700; Anal. Calcd for

$C_{19}H_{18}BF_2NO_2$: C, 66.89; H, 5.32; N, 4.11. Found: C, 67.23; H, 5.26; N, 4.17.

The procedure for the synthesis of substituted quinolin-2(1H)-one 3h

To a 50 mL round bottomed flask was added **2h** (686.3 mg, 2.0 mmol), DDQ (3.0 mmol) and CH_2Cl_2 (10 mL). The mixture was stirred at room temperature for 1.0 h. After the substrate **2g** was consumed completely as indicated by TLC, the mixture was poured into ice water, and then extracted with dichloromethane (3 × 20 mL), the combined organic phase was washed with water (3 × 20 mL), and dried over anhydrous Na_2SO_4 . The solvent was removed under reduced pressure, and the crude product was purified by flash chromatography (silica gel, petroleum ether: ethyl acetate 4:1) to give **3h** as colorless solid (469.3 mg, 80%).

3-Acetyl-6-methoxy-4-phenylquinolin-2(1H)-one (3h).

Yellow solid: mp 260-261 °C; 1H NMR (400 MHz, DMSO): δ 2.21 (s, 3H), 3.57 (s, 3H), 6.64 (d, $J = 2.4$ Hz, 1H), 7.24-7.27 (dd, $J_1 = 9.2$ Hz, $J_2 = 2.4$ Hz, 1H), 7.31 (s, 1H), 7.33 (d, $J = 2.4$ Hz, 1H), 7.37 (d, $J = 9.2$ Hz, 1H), 7.48-7.53 (m, 3H), 12.14 (s, 1H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 31.4, 55.2, 109.0, 117.0, 119.5, 119.8, 128.5, 128.7, 133.0, 133.7, 134.2, 146.4, 154.2, 158.8, 201.7; IR (KBr, cm^{-1}): 3446, 1703, 1647, 1597, 1497, 1281, 733, 702; Anal. Calcd for $C_{18}H_{15}NO_3$: C, 73.71; H, 5.15; N, 4.78. Found: C, 74.16; H, 5.20; N, 4.83.

Typical procedure for the synthesis of dihydropyridone-BF₂ complexes **5** (5a as an example).

To a 50 mL round bottomed flask was added **4a** (610.7 mg, 2.0 mmol), $BF_3 \cdot Et_2O$ (3.0 mmol) and DCE (10 mL). The mixture was stirred at 80 °C for 2.0 h. After the substrate **4a** was consumed completely as indicated by TLC, the mixture was poured into ice water, and then extracted with dichloromethane (3 × 20 mL), the combined organic phase was washed with water (3 × 20 mL), and dried over anhydrous Na_2SO_4 . The solvent was removed under reduced pressure, and the crude product was purified by flash chromatography (silica gel, petroleum ether: ethyl acetate 4:1) to give **5a** as a colorless solid (494.4 mg, 70%).

2,2-Difluoro-4-methyl-7-phenyl-8-(*p*-tolyl)-7,8-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]pyridin-1-ium-2-uide (5a)

Yellow solid: mp 189-192 °C; 1H NMR (300 MHz, DMSO): δ 2.21 (s, 3H), 2.27 (s, 3H), 4.55 (d, $J = 7.5$ Hz, 1H), 6.04-6.11 (dd, $J_1 = 15.6$ Hz, $J_2 = 7.5$ Hz, 1H), 6.34 (d, $J = 15.6$ Hz, 1H), 6.84 (d, $J = 8.1$ Hz, 1H), 6.99 (d, $J = 8.1$ Hz, 1H), 7.04 (s, 1H), 7.18-7.29 (m, 5H), 8.20 (s, 1H); ^{13}C NMR (100 MHz, DMSO): δ 20.1, 20.6, 94.2, 117.0, 124.5, 126.5, 127.6, 128.0, 128.6, 129.8, 130.5, 131.9, 134.9, 136.2, 163.5, 178.6; IR (KBr, cm^{-1}): 3346, 1622, 1595, 1529, 1501, 1167, 816, 770, 746, 689; Anal. Calcd for $C_{20}H_{18}BF_2NO_2$: C, 68.02; H, 5.14; N, 3.97. Found: C, 67.83; H, 5.21; N, 4.07.

2,2-Difluoro-8-(4-methoxyphenyl)-4-methyl-7-phenyl-7,8-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]pyridin-1-ium-2-uide (5b)

Yellow solid: mp 210-211 °C; 1H NMR (300 MHz, $CDCl_3$): δ 2.25 (s, 3H), 3.79 (s, 3H), 4.61 (d, $J = 7.5$ Hz, 1H), 6.08-6.16 (dd, $J_1 = 15.6$ Hz, $J_2 = 7.5$ Hz, 1H), 6.38 (d, $J = 15.6$ Hz, 1H), 6.76-6.79 (dd, $J_1 = 8.7$ Hz, $J_2 = 2.7$ Hz, 1H), 6.82 (d, $J = 2.7$ Hz, 1H), 6.91 (d, $J = 8.7$ Hz, 1H), 7.22-7.30 (m, 5H), 8.00 (s, 1H); ^{13}C NMR (100 MHz, DMSO): δ 19.9, 55.4, 93.8, 113.4, 114.6, 118.1, 126.0, 126.1, 126.4, 127.6, 128.1, 128.6, 131.8, 136.2, 157.0, 178.1; Anal. Calcd for $C_{20}H_{18}BF_2NO_3$: C, 65.07; H, 4.91; N, 3.79. Found: C, 65.53; H, 4.85; N, 3.91.

8-(4-Chlorophenyl)-2,2-difluoro-4-methyl-7-phenyl-7,8-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]pyridin-1-ium-2-uide (5c)

Yellow solid: mp 219-221 °C; 1H NMR (300 MHz, $CDCl_3$): δ 2.28 (s, 3H), 5.43 (d, $J = 3.9$ Hz, 1H), 5.49-5.54 (dd, $J_1 = 10.2$ Hz, $J_2 = 3.9$ Hz, 1H), 6.46 (d, $J = 10.2$ Hz, 1H), 6.84 (d, $J = 8.7$ Hz, 1H), 7.06-7.10 (m, 2H), 7.26 (s, 1H), 7.27-7.31 (m, 1H), 7.32 (d, $J = 1.5$ Hz, 1H), 7.34 (d, $J = 1.5$ Hz, 1H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 19.6, 68.5, 95.2, 118.0, 118.5, 127.7, 128.5, 129.1, 129.2, 129.6, 134.8, 135.8, 137.8, 164.8, 174.0; Anal. Calcd for $C_{19}H_{15}BClF_2NO_2$: C, 61.08; H, 4.05; N, 3.75. Found: C, 61.53; H, 4.16; N, 3.86.

8-(2-Chlorophenyl)-2,2-difluoro-7-(4-methoxyphenyl)-4-methyl-7,8-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]pyridin-1-ium-2-uide (5d) ($d/r = 5:3$)

Yellow solid: mp 151-155 °C; 1H NMR (major isomer) (400 MHz, DMSO): δ 2.29 (s, 3H), 3.73 (s, 3H), 5.50 (d, $J = 4.0$ Hz, 1H), 5.62-5.66 (dd, $J_1 = 12.0$ Hz, $J_2 = 4.0$ Hz, 1H), 6.42 (d, $J = 8.0$ Hz, 1H), 6.91 (d, $J = 12.0$ Hz, 2H), 7.13 (d, $J = 8.0$ Hz, 2H), 7.21 (t, $J = 8.0$ Hz, 1H), 7.44 (t, $J = 8.0$ Hz, 1H), 7.72 (d, $J = 8.0$ Hz, 1H); 1H NMR (minor isomer) (400 MHz, DMSO): δ 2.27 (s, 3H), 3.68 (s, 3H), 5.57-5.60 (dd, $J_1 = 12.0$ Hz, $J_2 = 4.0$ Hz, 1H), 5.93 (s, 1H), 6.71 (d, $J = 12.0$ Hz, 1H), 6.78 (d, $J = 12.0$ Hz, 2H), 6.99 (d, $J = 8.0$ Hz, 2H), 7.35-7.39 (m, 2H), 7.49-7.53 (m, 1H), 7.87 (d, $J = 8.0$ Hz, 1H); ^{13}C NMR (100 MHz, DMSO): δ 19.7, 19.8, 55.4, 55.5, 66.0, 67.5, 95.2, 95.3, 113.8, 114.6, 118.0, 118.7, 119.2, 119.3, 128.1, 128.9, 130.4, 131.1, 134.4, 135.1, 159.9, 160.0, 163.8, 164.9, 173.3, 174.4; Anal. Calcd for $C_{20}H_{17}BClF_2NO_3$: C, 59.52; H, 4.25; N, 3.47. Found: C, 59.91; H, 4.36; N, 3.40.

Crystal data for **5d**: $C_{20}H_{17}BClF_2NO_3$, colorless crystal, $M = 871.29$, P-1, $a = 7.643(5)$ Å, $b = 12.269(5)$ Å, $c = 12.840(5)$ Å, $\alpha = 101.954(5)^\circ$, $\beta = 104.028(5)^\circ$, $\gamma = 98.284(5)^\circ$, $V = 1118.6(10)$ Å³, $Z = 1$, $T = 293(2)$ K, $F(000) = 450$, $R = 0.0123$. CCDC deposition number: 938933. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Center, 12 Union Road, Cambridge CB21EZ, UK; fax: (+44)1223-336-033; or deposit@ccdc.cam.ac.uk).

2,2-Difluoro-7-(4-methoxyphenyl)-4-methyl-8-(*o*-tolyl)-7,8-dihydro-2H-[1,3,2]dioxaborinino[4,5-*b*]pyridin-1-ium-2-uide (5e)

Yellow solid: mp 182-183 °C; 1H NMR (300 MHz, $CDCl_3$): δ 2.27 (s, 3H), 2.31 (s, 3H), 3.79 (s, 3H), 4.62 (d, $J = 7.2$ Hz, 1H), 5.94-6.01 (dd, $J_1 = 15.6$ Hz, $J_2 = 7.2$ Hz, 1H), 6.30 (d, $J = 15.6$ Hz, 1H), 6.81 (d, $J = 8.7$ Hz, 2H), 7.06-7.08 (m, 2H), 7.15-7.18 (m, 1H), 7.23

(s, 1H), 7.66 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 16.5, 20.7, 40.8, 55.3, 94.2, 114.0, 124.1, 124.4, 125.5, 127.4, 127.7, 128.6, 128.7, 129.7, 130.4, 159.4, 164.3, 181.7; IR (KBr, cm⁻¹): 1630, 1601, 1560, 1512, 1252, 1180, 827, 764; Anal. Calcd for C₂₁H₂₀BF₂NO₃: C, 65.82; H, 5.26; N, 3.66. Found: C, 66.03; H, 5.31; N, 3.57.

2,2-Difluoro-4-methyl-7,8-di-*p*-tolyl-7,8-dihydro-2*H*-[1,3,2]dioxaborinino[4,5-*b*]pyridin-1-ium-2-uide (5f)

Yellow solid; mp 219–221 °C; ¹H NMR (300 MHz, CDCl₃): δ 2.24 (s, 3H), 2.30 (s, 3H), 2.31 (s, 3H), 4.57 (d, *J* = 7.5 Hz, 1H), 6.02–6.10 (dd, *J*₁ = 15.6 Hz, *J*₂ = 7.5 Hz, 1H), 6.34 (d, *J* = 15.6 Hz, 1H), 6.85 (d, *J* = 8.1 Hz, 1H), 7.03 (d, *J* = 8.1 Hz, 1H), 7.09 (d, *J* = 8.1 Hz, 3H), 7.21 (d, *J* = 8.1 Hz, 2H), 8.02 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 20.6, 20.9, 21.1, 40.8, 94.4, 116.9, 124.0, 126.4, 128.9, 129.0, 129.2, 129.6, 129.7, 129.8, 133.3, 135.8, 137.7, 163.8, 180.4; IR (KBr, cm⁻¹): 3344, 1626, 1599, 1529, 1500, 1207, 1163, 814; Anal. Calcd for C₂₁H₂₀BF₂NO₂: C, 68.69; H, 5.49; N, 3.81. Found: C, 68.36; H, 5.54; N, 3.84.

Acknowledgements

Financial support of this research by the National Natural Science Foundation of China (21172211) and Department of Science and Technology of Jilin Province (201105030 and 201205027) are greatly acknowledged.

Notes and references

Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China. Fax: +86 431 85262740; Tel: +86 431 85262676; E-mail: ning.zhang@ciac.ac.cn, dwdong@ciac.ac.cn

†Electronic Supplementary Information (ESI) available: Experimental details, spectral and analytical data, copies of ¹H NMR and ¹³C NMR spectra for new compounds **1–3** and **5**, and CIF files for **2g** and **5d**. See DOI: 10.1039/b000000x/

- (a) A. D. Elbein, R. J. Molyneux, *Alkaloids: Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; Wiley: New York, 1990; Vol. 5, pp 1–54. (b) G. Jones, *Pyridines and Their Benzo Derivatives: Synthesis in Comprehensive Heterocyclic Chemistry II*; A. McKillop, Ed.; Pergamon Press: Oxford, 1996; Vol. 5, p 167. (c) Q. Li, L. A. Mitscher, L. L. Shen, *Med. Res. Rev.* 2000, **20**, 231.
- (a) E. F. V. Scriven, In *Comprehensive Heterocyclic Chemistry*; A. R. Katritzky, C. W. Rees, Eds.; Pergamon Press: Oxford, 1984; Vol. 2. (b) G. Jones, *Pyridines and Their Benzo Derivatives: Synthesis*. In: A. Boulton, A. McKillop, (eds) *Comprehensive Heterocyclic Chemistry*. Pergamon Press, Oxford, 1984, p 395/Chap. 2.08.
- C. B. Fischer, H. Steininger, D. S. Stephenson, H. Zipse, *J. Phys. Org. Chem.* 2005, **18**, 901.
- J. M. Rawson, R. E. P. Winpenny, *Coord. Chem. Rev.* 1995, **139**, 313.
- (a) M. Torres, S. Gil, M. Parra, *Curr. Org. Chem.* 2005, **9**, 1757. (b) G. M. Strunz, J. A. Findlay, *The Alkaloids*; A. Brossi, Ed.; Academic Press: Orlando, 1985; Vol. 26, p 89. (c) V. P. Litvinov, *Russ. Chem. Rev.* 2003, **72**, 69.
- (a) L. Jayasinghe, H. K. Abbas, M. R. Jacob, W. H. M. W. Herath, N. P. D. Nanayakkara, *J. Nat. Prod* 2006, **69**, 439. (b) P. R. Angibaud, M. G. Venet, W. Filliers, R. Broeckx, Y. A. Ligny, P. Muller, V. S. Poncelet, D. W. End, *Eur. J. Org. Chem.* 2004, 479. (c) M. F. Grundon,

- Nat. Prod. Rep.* 1989, **6**, 523. (d) R. Fujita, K. Watanabe, W. Ikeura, Y. H. Ohtake, *Heterocycles* 2000, **53**, 2607.
- (a) G. B. Fodor, B. Colasanti, *Alkaloids: Chemical and Biological Perspectives*; S. W. Pelletier, Ed.; Wiley: New York, 1985; Vol. 3, pp 49–73. (b) H. Hong, D. L. Comins, *J. Org. Chem.* 1996, **61**, 391. (c) D. L. Comins, J. M. Nolan, *Org. Lett.* 2001, **3**, 4255.
 - (a) H. Decker, *Chem. Ber.* 1892, **25**, 443. (b) D. L. Comins, J. K. Saha, *J. Org. Chem.* 1996, **61**, 9623. (c) W. Du, *Tetrahedron* 2003, **59**, 8649.
 - (a) D. L. Comins, J. L. Gao, *Tetrahedron Lett.* 1994, **35**, 2819. (b) T. Hu, C. Li, *Org. Lett.* 2005, **7**, 2035. (c) H. J. Cristau, P. P. Cellier, J. F. Spindler, M. Taillefer, *Chem. Eur. J.* 2004, **10**, 5607.
 - (a) M. Wasa, J.-Q. Yu, *J. Am. Chem. Soc.* 2008, **130**, 14058. (b) K. Inamoto, T. Saito, K. Hiroya, T. Doi, *J. Org. Chem.* 2010, **75**, 3900.
 - (a) C. Fiorelli, D. Savoia, *J. Org. Chem.* 2007, **72**, 6022. (b) J. H. Lee, S. Shin, J. Kang, S. G. Lee, *J. Org. Chem.* 2007, **72**, 7443.
 - (a) Z. Chen, L. Lin, D. Chen, J. Li, X. Liu, X. Feng, *Tetrahedron Lett.* 2010, **51**, 3088. (b) J. Itoh, K. Fuchibe, T. Akiyama, *Angew. Chem., Int. Ed.* 2006, **45**, 4796.
 - (a) A. P. De Silva, H. Q. N. Gunaratne, T. Gunnlaugsson, A. J. M. Huxley, C. P. McCoy, J. T. Rademacher, T. E. Rice, *Chem. Rev.* 1997, **97**, 1515. (b) M. Wang, D. Q. Zhang, G. X. Zhang, D. B. Zhu, *Chem. Commun.* 2008, 4469.
 - (a) W. Yang, H. He, D. G. Drueckhammer, *Angew. Chem. Int. Ed.* 2001, **4**, 1714. (b) K. Rurack, M. Kollmannsberger, J. Daub, *Angew. Chem., Int. Ed.* 2001, **40**, 385.
 - (a) C. T. Chen, *Chem. Mater.* 2004, **16**, 4389. (b) Q. D. Liu, M. S. Mudadu, R. Thummel, Y. Tao, S. N. Wang, *Adv. Funct. Mater.* 2005, **15**, 143.
 - (a) G. T. Morgan, R. B. Tunstall, *J. Chem. Soc. Trans.* 1924, **125**, 1963. (b) V. A. Reutov, E. V. Gukhman, *Russ. J. Gen. Chem.* 1999, 1603. (c) H. Maeda, Y. Ito, *Inorg. Chem.* 2006, **45**, 8205.
 - (a) H. D. Ilge, E. Birckner, D. Fassler, *J. Photochem.* 1986, **32**, 177. (b) A. G. Mirochink, E. V. Fedorenko, G. Kh. Gizzatulina, V. E. Karasev, *Russ. J. Phys. Chem. A* 2007, **81**, 1880. (c) E. Cogné-Laage, J.-F. Allemant, O. Ruel, J.-B. Baudin, V. Croquette, M. Blanchard-Desce, L. Julien, *Chem. Eur. J.* 2004, **10**, 1445. (d) G. Zhang, J. Chen, S. J. Payne, S. E. Kooi, J. N. Demas, C. L. Fraser, *J. Am. Chem. Soc.* 2007, **129**, 8942. (e) G. Zhang, J. Lu, M. Sabat, C. L. Fraser, *J. Am. Chem. Soc.* 2010, **132**, 2160.
 - (a) W. Pan, D. Dong, K. Wang, J. Zhang, R. Wu, D. Xiang, Q. Liu, *Org. Lett.* 2007, **9**, 2421. (b) D. Xiang, Y. Yang, R. Zhang, Y. Liang, W. Pan, J. Huang, D. Dong, *J. Org. Chem.* 2007, **72**, 8593. (c) D. Xiang, K. Wang, Y. Liang, G. Zhou, D. Dong, *Org. Lett.* 2008, **10**, 345. (d) R. Zhang, D. Zhang, Y. Guo, G. Zhou, Z. Jiang, D. Dong, *J. Org. Chem.* 2008, **73**, 9504.
 - X. Liu, Q. Zhang, D. Zhang, X. Xin, R. Zhang, F. Zhou, D. Dong, *Org. Lett.* 2013, **15**, 776.
 - X. Liu, X. Xin, D. Xiang, R. Zhang, S. Kumar, F. Zhou, D. Dong, *Org. Biomol. Chem.* 2012, **10**, 5643.
 - X. Liu, N. Zhang, J. Yang, Y. Liang, R. Zhang, D. Dong, *J. Org. Chem.* 2013, **78**, 3323.
 - A. K. Zarif, S. Y. Amal, *J. Indian. Chem. Soc.* 1981, **58**, 168.
 - For Knorr quinolin-2(1*H*)-one synthesis, see: (a) L. Knorr, *Ann.* 1886, **236**, 69. (b) F. W. Bergstorm, *Chem. Rev.* 1944, **35**, 157.
 - L.-H. Xie, X.-Y. Hou, Y.-R. Hua, C. Tang, F. Liu, Q.-L. Fan, W. Huang, *Org. Lett.* 2006, **8**, 3701.

Cite this: DOI: 10.1039/c0xx00000x


www.rsc.org/xxxxxx

ARTICLE

BF₃·Et₂O-Mediated Intramolecular Cyclization of Unsaturated Amides: Convenient Synthesis of Dihydroquinolin-2-one-BF₂ Complexes[†]Xu Liu, Qian Zhang, Xiaoqing Xin, Rui Zhang, Ning Zhang,* Yongjiu Liang, and Dewen Dong*
DOI: 10.1039/b000000x

5

Graphic Abstract



10

A facile and efficient synthesis of substituted dihydroquinolin-2-one-BF₂ complexes is developed *via* intramolecular cyclization of α -acyl acrylamides and α -acyl cinnamamides mediated by BF₃·Et₂O, respectively.

15